title: Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.
authors.affiliation: Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Heon
authors.forename: Beow Y
authors.initials: BY
authors.lastname: Yeap
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Britt
authors.forename: Daniel B
authors.initials: DB
authors.lastname: Costa
authors.forename: Michael S
authors.initials: MS
authors.lastname: Rabin
authors.forename: David M
authors.initials: DM
authors.lastname: Jackman
authors.forename: Bruce E
authors.initials: BE
authors.lastname: Johnson
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D016543:Central Nervous System Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000401:mortality / Q000556:secondary*; D018450:Disease Progression; D000069347:Erlotinib Hydrochloride; D005260:Female; D000077156:Gefitinib; D018773:Genes, erbB-1 / Q000502:physiology*; D005838:Genotype; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000502:physiology; D009367:Neoplasm Staging; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib